EU Clinical Trial 2019-001020-36

RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATION-CONTROLLED, MULTICENTER, PARALLEL-DOSE COMPARISON TRIAL.  May 31, 2019

Main objective of the trial: The primary objective of the study is to demonstrate the safety and efficacy of rhIGF-1 in promoting the growth of children with growth failure associated with Primary IGFD.

Parties

Sponsors
Countries
EU US
Keywords
Increlex MECASERMIN

JSON preview

Similar records

Title

Source:  EMA Last updated:  Jun 5, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.